Adaptive Biotechnologies reported after the close of the market on Wednesday that its fourth quarter revenues increased 41 percent year over year.

Grail is making some headway in its mission to develop a liquid biopsy solution to detect cancer early. The Menlo Park, CA-based company said it has initiated PATHFINDER, a multi-center study.

Quest Diagnostics said it has acquired Blueprint Genetics in an all-cash equity transaction.

Researchers at the Laboratory of Bionanophotonic Systems (BIOS) at EPFL's School of Engineering have developed an optical biosensor that slashes the sepsis diagnosis time from several days to just a few minutes.

FDA has issued an emergency use authorization (EUA) for the Centers for Disease Control and Prevention’s Coronavirus detection test.

Cardinal Health nixed its relationship with Suqian, China-based Siyang Holymed after learning that the FDA-authorized supplier had shifted production of Cardinal's surgical gowns to non-approved sites without the proper controlled environments.

Jabil Inc. is consolidating its healthcare businesses under Jabil Healthcare.

Researchers from Link?ping University are behind a new study that has used artificial intelligence to investigate whether it is possible to discover biological networks using deep learning......

Additional benefits include a patient preferred design, improved battery longevity and MRI compatibility.

Lucid Diagnostics announced recently it has entered a research agreement with the Fred Hutchinson Cancer Research Center to evaluate the center's Barrett's Esophagus progression biomarkers using Lucid's EsoCheck Esophageal Cell Collection Device.

Novacyt said recently that its molecular test for the COVID-19 virus has received CE marking.

10x Genomics reported after the close of the market recently a 49 percent increase in fourth quarter revenues driven by consumables sales.

Agilent Technologies reported after the close of the market recently that its fiscal first quarter revenues rose 6 percent year over year.

Invitae reported after the close of the market recently that its fourth quarter 2019 revenues increased 47 percent from the prior year.

Diagnostics manufacturer Quidel reported after the close of the market recently that its fourth quarter revenues rose 15 percent year over year, due primarily to growth in its rapid immunoassay business.